Search results
Ozempic, Wegovy May Protect Kidney Health, New Research Finds
Health.com· 2 days agoOzempic and Wegovy are used to treat type 2 diabetes and obesity, respectively, but they may also be...
Will FLiRT COVID variants bring another summer surge? What to know about symptoms and potential for...
Fortune via Yahoo Finance· 7 days agoThese data point to FLiRT variants causing less severe infection than variants past, Michael says....
Young athletes at risk for hypertension, future complications
Deseret News via Yahoo News· 20 hours agoDespite being perceived as a generally healthy population, young athletes are not immune to heart ...
Jordan Chiles' Beyoncé-Inspired Leotard Used 4,400 Swarovski Crystals
Women s Health· 7 days agoOn May 31, the Olympic silver medalist donned a custom leotard inspired by a Beyoncé look during the...
ProKidney ends manufacturing pause, has positive clinical trial results
Winston-Salem Journal· 1 day agoProKidney Corp. disclosed in a regulatory filing Monday it resumed U.S. manufacturing on June 1 as...
Lisata Therapeutics (NASDAQ:LSTA) Stock Price Up 6.4%
ETF DAILY NEWS· 12 hours agoLisata Therapeutics, Inc. (NASDAQ:LSTA – Get Free Report) shares traded up 6.4% on Tuesday . The stock traded as high as $3.70 and last traded at $3.67.
Ozempic Just Got Even More Bullish For Novo Nordisk Stock, Yet Again
Motley Fool via Yahoo Finance· 6 days agoThe Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. *Stock Advisor...
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and...
Benzinga· 2 days agoWINSTON-SALEM, N.C., June 10, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. PROK ("ProKidney"), a leading late clinical-stage cellular therapeutics company focused on chronic & ...
Another potential indication for Mounjaro, Zepbound
Becker’s Hospital Review· 1 day agoThe trial results could precede another indication for the popular drugs. Mounjaro, a Type 2 diabetes medication, and Zepbound, a weight loss injection, are part of a booming class of drugs ...
ProKidney (NASDAQ:PROK) Given New $6.00 Price Target at Jefferies Financial Group
ETF DAILY NEWS· 1 day agoProKidney (NASDAQ:PROK – Free Report) had its target price reduced by Jefferies Financial Group from $15.00 to $6.00 in a research note released on Monday, Benzinga reports. Jefferies Financial ...
